Cationic Lipid Complex for Nucleic Acid Delivery Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cationic lipids used for nucleic acid delivery face challenges such as instability during storage, aggregation, and inefficient release of nucleic acids into the cytoplasm, which affects their therapeutic efficacy.
Innovation Solution
A novel cationic lipid compound represented by specific formulae, combined with neutral lipids, polyethylene glycol-modified lipids, and sterols, forms a lipid complex that effectively encapsulates nucleic acids and maintains physical stability over time, preventing particle diameter increase and ensuring efficient release into the cytoplasm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic lipids are used for nucleic acid delivery, then nucleic acid can be protected from decomposition and penetrate cell membrane, but the particles are likely to aggregate during storage
Solution Approach 1:
The patent employs composite lipid structures combining cationic lipid moieties with specific hydrophobic chains and polar head groups. The cationic lipid component provides nucleic acid binding and cellular uptake, while the engineered hydrophobic and hydrophilic regions create steric and electrostatic barriers that prevent aggregation during storage, thus resolving the contradiction between delivery efficiency and storage stability.
Solution Approach 2:
The patent modifies physical and chemical parameters of the lipid molecules, including chain length, saturation degree, and head group composition. These parameter changes optimize the balance between membrane interaction (for delivery) and particle stability (for storage), allowing the system to maintain both high delivery efficiency and storage stability under different conditions.
2Quantity of substance
If conventional cationic lipids are used, then nucleic acid encapsulation is achieved, but inefficient release of nucleic acids into the cytoplasm occurs
Solution Approach 1:
The patent designs lipids with dynamic properties that respond to cellular environments. The cationic lipid structure allows for conformational changes and interactions with cellular membranes that facilitate endosomal escape and cytoplasmic release. This dynamic behavior enables efficient nucleic acid delivery while maintaining stable encapsulation during circulation.
Solution Approach 2:
The cationic lipid acts as an intermediary between the nucleic acid payload and the cellular target. Its amphiphilic structure with specific head groups (such as phosphocholine or phosphoethanolamine derivatives) mediates interactions with cell membranes and endosomal compartments, enabling efficient transfection while protecting the nucleic acid until release.
Data Source
Figure 1~2
AI summary
The present invention provides a cationic lipid which is able to be used for nucleic acid delivery to the cytoplasm. A cationic lipid according to the present invention is, for example, a compound represented by formula (1a) or a pharmaceutically acceptable salt thereof. (In formula (1a), each of L1 and L2 independently represent an alkylene group having 3-10 carbon atoms; each of R1 and R2 independently represent an alkyl group having 4-22 carbon atoms or an alkenyl group having 4-22 carbon atoms; X1 represents a single bond or -CO-O-; and ring P represents one of formulae (P-1) to (P-5).)(In formulae (P-1) to (P-5), R3 represents an alkyl group having 1-3 carbon atoms.)